🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today Carlo M. Cicala's family sent us two typical easter dishes from Naples: Casatiello and Pastiera. Buon appetito!

Happy Sant Jordi from the Sarcoma laboratory members! 🐉🌹 Vall d’Hebron Institute of Oncology (VHIO)

Meet Francesca! Francesca Esposito has joined our laboratory from Pavia, Italy, for a three-month stay. She will study the role of DNA damage in sarcomas during her time here.

💙 ¡Gracias, Asociación Iker‼️ Por vuestro compromiso en la investigación del #LiposarcomaMixoide que se lleva a cabo en el Grupo de Investigación Traslacional que dirige César Serrano García. ➕ linke.to/AsociacionIker…

🤩¡Empezamos 2025 con buenas noticias!: abrimos en el Vall d’Hebron Institute of Oncology (VHIO) el ensayo Fase II OSTEOMYC para investigar lel inhibidor de Myc OMO-103 en pacientes con #osteosarcoma que tengan 12 años o más. Gracias a The Osteosarcoma Institute y PEPTOMYC por hacerlo posible Info➡️clinicaltrials.gov/study/NCT06650…

‼️mTOR and/or PI3K inhibitors can be an effective treatment in #GIST SDH-deficient 🧬Activating mutations in the PI3K/mTOR pathway in relapsed/mts samples 💊Sustained 55-months response with everolimus 🧐We provide other insights on tumor evolution 📰ascopubs.org/doi/10.1200/PO…

Targeted Next-Generation Sequencing in Succinate Dehydrogenase–Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway: brnw.ch/21wQ98s #GastrointestinalCancer #gicsm Co-authored by @drcesarcoma, Carlo M. Cicala and @serrano_lab

🧐Willing to stay tuned for the latest advances and upcoming efforts in #ClinicalTrials in #Sarcomas? Check this review nicely arranged by Diego Gomez-Puerto Serrano Lab and colleagues from Vall d’Hebron Institute of Oncology (VHIO) Vall d'Hebron just out of the oven 🔥 ➡️tandfonline.com/doi/10.1080/14…